PHILADELPHIA, Aug. 29, 2012 /PRNewswire/ -- Bioquark, Inc., (www.bioquark.com) a biopharmaceutical company engaged in the development of proprietary biological drugs that can be simultaneously leveraged for both the regeneration and repair of human organs and tissues, today announced that Ira S. Pastor, Chief Executive Officer, will present the Company’s overview at the Rodman and Renshaw Annual Global Investment Conference’s (14th Annual Healthcare Conference) on Tuesday, September 11, 2012, at 10:00 a.m. Eastern time at the Waldorf Astoria Hotel in New York City.
“The Rodman and Renshaw Conference is one of the year’s most effective opportunities to present to investors and analysts,” said Pastor. “As such, it represents a key step becoming a public company.”
“Being represented by JSBarkats as our securities counsel, we benefit from both the experience and the network, not to mention the unprecedented value added strategy,” added Mark Corrao, Bioquark’s Chief Financial Officer.
About Bioquark, Inc.
Bioquark, Inc. is developing proprietary biologics that can be simultaneously applied for both regeneration and repair of human organs and tissues. To date, Bioquark has demonstrated direct microenvironment remodeling of diseased, damaged, and aged tissues in mammals, utilizing its lead development candidate, BQ-A. With global healthcare costs now surpassing $6 trillion annually, and the majority being spent on diseases with underlying cellular degeneration or damage component, BQ-A represents a lucrative and transformational therapeutic opportunity.
About Rodman & Renshaw, LLC
Rodman & Renshaw Capital Group, Inc. is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC. Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. For more information visit Rodman & Renshaw on the Internet at www.rodm.com
About JSBarkats, PLLC
JSBarkats PLLC (http://www.jsbarkats.com/) is a full service law firm with offices in New York City. The firm provides experienced, efficient, and cost-effective legal services to institutional and well as small and mid-sized corporate clients and individuals. In addition to its corporate securities group located in NY, the firm specializes in Life Sciences. With 22 attorneys JSBarkats provides legal services in the following areas: corporate, securities, commercial litigation immigration, intellectual property, real estate, start-ups re-structuring; tax law and and bankruptcy.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the proposed public offering and the intended use of proceeds from the offering and statements about plans for the development of our product candidates. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements also are subject to risks, uncertainties and assumptions relating to the development of our product candidates, including those detailed from time to time in our filings with the SEC, and represent our views only as of the date they are made and should not be relied upon as representing our views as of any subsequent date. Our actual results may differ materially from those contemplated by these forward-looking statements. We do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this press release.
Contact:
Ira S Pastor
CEO
Bioquark Inc.
267-971-7725
pastor@bioquark.com
SOURCE Bioquark Inc.
